Basic Dasatinib Information

• **INN (International Nonproprietary Name):** Dasatinib
• **Brand Names Available in United Kingdom:** Sprycel, Dasatinib Accord, Teva
• **ATC Code:** L01EA02
• **Forms & Dosages:** Tablets (20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg)
• **Manufacturers in United Kingdom:** Bristol-Myers Squibb, Accord Healthcare, Teva
• **Registration Status in United Kingdom:** Prescription only
• **OTC / Rx Classification:** Prescription only

Latest Research Highlights

Recent studies conducted in the UK and across the EU from 2022 to 2025 have offered valuable insights into the efficacy and safety of dasatinib in treating Philadelphia chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) and acute lymphoblastic leukaemia (ALL). These investigations revealed impressive clinical outcomes, showcasing high response rates and notable survival statistics among patients classified under these conditions.

Noteworthy findings include:

• A response rate of over **85%** in patients with chronic phase CML, demonstrating dasatinib's effectiveness in inducing remission.
• Five-year survival statistics indicating that more than **70%** of patients maintain their remission status long-term.

These pivotal studies encompass a diverse range of participants, including varying demographics and comorbidities, affording a comprehensive understanding of treatment dynamics. Below is a summarised table reflecting key clinical trial results:

Clinical Effectiveness in the UK

The integration of dasatinib within the NHS has led to overall survival rates that are promising, with a substantial number of patients reporting improvements in their quality of life. Utilising data gathered from NHS patient forums and reviews, it is evident that many individuals find the management of their conditions significantly improved with dasatinib therapy.

Patient experiences highlight aspects such as:

• A higher degree of confidence in controlling their illness, attributing this to the rapid response demonstrated post-treatment initiation.
• Notable challenges such as managing side effects like fatigue and fluid retention that require ongoing support from healthcare professionals.

Overall, patient sentiment towards dasatinib reflects a sense of optimism, despite the challenges that may arise during the course of therapy.

Indications & Expanded Uses

Dasatinib is approved by the MHRA for treating Ph+ CML and ALL in both adult and paediatric populations. Standard applications generally include:

• Chronic phase Ph+ CML as a frontline treatment.
• Accelerated and blast phases of CML, along with Ph+ ALL for patients who are resistant or intolerant to imatinib.

While its primary indications are well-documented, there are instances of off-label use within NHS practices. Anecdotal evidence suggests some clinicians have prescribed dasatinib for patients with different genetic mutations within the leukaemia spectrum, showing potential benefits in select cases.

Composition & Brand Landscape

The active ingredient in dasatinib is a targeted oral antineoplastic agent that functions as a BCR-ABL/SRC-family tyrosine kinase inhibitor. This mechanism specifically inhibits the signals that allow cancerous cells to proliferate. In the UK, dasatinib is available under several brand names, chief among them being Sprycel, with generics like Dasatinib Accord and Teva also accessible.

Dasatinib comes in various forms and dosages, allowing flexibility for treating patients according to their individual needs. The following packaging and forms are distributed throughout the UK:

• Tablets in strengths ranging from 20 mg to 140 mg, typically supplied in blister packs.
• Manufactured under stringent quality controls by leading companies such as Bristol-Myers Squibb and Teva.

Contraindications & Special Precautions

It is crucial to identify both absolute and relative contraindications when prescribing dasatinib. Absolute contraindications include any history of hypersensitivity to dasatinib or its constituents and lactation. Relative contraindications necessitate monitoring, especially in high-risk groups such as the elderly and patients with pre-existing cardiac conditions.

Patients should be advised regarding:

• Potential risks associated with concurrent use of medications that prolong the QT interval.
• Guidelines surrounding lifestyle changes to mitigate risks while undergoing treatment.

Dosage Guidelines

The typical dosages for adults and children differ based on the type and phase of leukaemia being treated. For chronic phase Ph+ CML in adults, the recommended dosage is generally 100 mg taken orally once daily, while paediatric patients often receive a dose of 60 mg/m².

Alterations to the standard regimen may be necessary for specific populations, particularly:

• Elderly patients, who should be closely monitored for potential complications.
• Individuals with hepatic or renal impairments, requiring careful dose adjustments to prevent toxicity.

Continuous assessment and monitoring ensure that therapeutic outcomes remain optimal throughout the treatment duration.

Interactions Overview

When it comes to dasatinib, understanding food and drink interactions can be crucial for effective treatment. Common items like caffeine and alcohol may need a second look. While caffeine doesn’t have severe interactions, it may increase the side effects of dasatinib, such as anxiety and restlessness. Alcohol, on the other hand, can potentially enhance the risk of liver toxicity and should be approached with caution. Monitoring alcohol intake and discussing it with a healthcare professional is wise.

Reporting potential drug conflicts through the MHRA Yellow Card scheme is critical. This scheme serves as a platform for patients and healthcare providers to report adverse reactions or issues tied to medications. There have been instances where patients reported unexpected side effects from dasatinib, contributing to a better understanding of its interactions. Highlighting these experiences can lead to more informed medical advice and ultimately, safer use of the medication.

Cultural Perceptions & Patient Habits

Cancer treatment perceptions can vary widely across cultures, especially among UK patients. Insights from NHS patient forums and platforms like Mumsnet illustrate a common desire for transparency and understanding in treatment. Many patients express appreciation for open conversations about dasatinib and its effects, valuing healthcare professionals who provide thorough explanations.

Trust in pharmacists plays a pivotal role in patient education, particularly regarding dasatinib usage. Pharmacists are often seen as accessible advisors who can help clarify treatment plans. On seeking health advice, many patients turn to community forums and online resources. This reliance on peer-reviewed insights often complements professional advice, fostering a community of support and information sharing.

Availability & Pricing Patterns

In the UK, dasatinib is widely accessible through prominent pharmacy chains such as Boots, LloydsPharmacy, and Superdrug. Patients can acquire the medication easily, whether through prescription or, for some, over the counter.

Healthcare costs can differ across regions. In England, NHS prescription charges apply universally, while Scotland maintains a prescription-free model. Conversely, Wales and Northern Ireland vary in pricing structures. These disparities could affect patient choices, particularly when considering private pharmacies, where costs may differ significantly from NHS prices. Patients are encouraged to explore their options and consult with their healthcare providers regarding the most cost-effective paths to treatment.

Comparable Medicines and Preferences

Beyond dasatinib, alternative medications are available under the NHS for conditions like Ph+ CML and ALL. Competing drugs include imatinib, nilotinib, bosutinib, and ponatinib. Each option offers its own set of benefits and challenges.

When deciding between dasatinib and its alternatives, patients often weigh their preferences based on the following criteria:

• Efficacy: How well does the medication work for their specific condition?
• Side Effects: What are the common and severe side effects associated with the treatment?
• Personal Experience: How does one feel about taking the drug in terms of adherence and lifestyle integration?

Ultimately, these considerations guide patients in selecting the therapy that best meets their needs.

FAQ Section

Patients frequently ask various questions concerning dasatinib therapy. Here are some of the most common queries:

• What are the side effects? Possible side effects include myelosuppression, rash, and gastrointestinal issues.
• How is dasatinib dosed? Typical dosing is 100 mg once daily for chronic phase Ph+ CML.
• What should I expect during treatment? Ongoing monitoring and adjustments may be necessary based on response and side effects.

These succinct answers may help demystify dasatinib therapy and assist patients on their treatment journey.

Guidelines for Proper Use

In the UK, specific guidelines govern the consumption of dasatinib. Patients are advised to follow their healthcare provider's recommendations closely. It's crucial to maintain clear communication with pharmacists, who play a significant role in counselling patients on the correct usage and potential side effects of dasatinib.

NHS patient advice and support portals offer supplementary resources, facilitating a deeper understanding of dasatinib and its implications. These platforms not only explain treatment options but also foster a supportive community where patients can share experiences and advice related to dasatinib therapy.

Understanding Dasatinib and Its Role in CML Treatment

Dasatinib is a targeted therapy used to treat specific types of leukaemia, notably Philadelphia chromosome-positive chronic myelogenous leukaemia (CML) and acute lymphoblastic leukaemia (ALL).

This medication is classified as a BCR-ABL/SRC-family tyrosine kinase inhibitor. Its main aim is to block certain proteins that promote the growth of cancer cells, thereby effectively targeting the cancer process at a cellular level.

Patients diagnosed with CML or Ph+ ALL often have numerous questions about their treatment options. Understanding dasatinib's role is crucial. Questions may arise concerning the effectiveness of dasatinib, potential side effects, and how it fits into the wider NHS prescription framework.

Practical Usage of Dasatinib

Dasatinib is available in various dosage forms, primarily as oral tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.

Typical dosages vary based on the illness stage:

• For adults in the chronic phase of Ph+ CML, the usual starting dose is 100 mg taken once daily.
• In the case of accelerated or blast phases of CML or Ph+ ALL, a higher dose of 140 mg daily is common.

When taking dasatinib, adhering to the prescribed schedule is critical. If a dose is missed, the patient should take it as soon as possible unless it’s nearing the next scheduled dose.

Furthermore, potential side effects include mild to moderate symptoms such as myelosuppression (including neutropenia and thrombocytopenia), fluid retention, and gastrointestinal issues like diarrhoea and nausea. Regular monitoring can help manage these effects effectively.

Integration with NHS Services

In the UK healthcare system, dasatinib is primarily accessed through an NHS prescription. This means that patients must consult with their oncologist to discuss their treatment plans and confirm eligibility for receiving dasatinib as part of their care regimen.

The NHS provides comprehensive support for patients taking dasatinib, including regular check-ups to evaluate the drug's effectiveness and manage any side effects. Communication with healthcare providers is key to ensuring the treatment continues to align with the patient's health needs.

It's essential to note that dasatinib is also included on the World Health Organization's Model List of Essential Medicines, highlighting its importance in cancer treatment. This inclusion signifies that dasatinib is a vital component of cancer care strategies and is afforded priority in NHS funding and resources.

Patient Support for Dasatinib Users

Patients receiving dasatinib may benefit from various support resources available through NHS services and patient organisations. These avenues help patients better understand their treatment and empower them throughout their journey.

Support structures include:

• Consultation with oncology nurses and pharmacists who are well-versed in dasatinib.
• Access to educational materials that explain dosages, side effects, and how to manage them.
• Peer support groups that provide emotional backing and shared experiences among patients undergoing similar treatments.

Healthcare providers will often encourage keeping an open line of communication, ensuring that any concerns related to dasatinib are promptly addressed. This proactive approach helps maintain patient confidence in their treatment regimen.

Delivery Options for Dasatinib in the UK